News | July 10, 2024
Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
The Unit has been issued GMP Certification from ANVISA-Brazil
The Unit has been issued GMP Certification from ANVISA-Brazil
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Both organisations enter into a long- term collaboration to expand patient access in India
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
